Work Here?
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Overview
Scorpion Therapeutics develops precision oncology drugs that target validated cancer drivers. It designs therapies with high target selectivity and favorable pharmacology, using biology, chemistry, proteomics, and computation, then partners with large pharmaceutical companies to fund and scale development. It differentiates itself through a target-driven science approach and strategic collaborations with milestone and royalty terms. The goal is to deliver fast, precise, and potent cancer treatments and bring them to patients worldwide through partnerships.
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
Get referred to Scorpion Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Lilly’s acquisition of STX-478 validates Scorpion’s platform and raises partnering value.
- Positive STX-478 data support expansion into breast and other solid tumors.
- Follow-on programs like STX-721 could create additional licensing or acquisition opportunities.
What critics are saying
- Value remains concentrated in STX-478 and one buyer, Lilly.
- Clinical setbacks in efficacy or safety would rapidly damage valuation and financing options.
- Small pipeline depth leaves little buffer if one program fails or stalls.
What makes Scorpion Therapeutics unique
- Integrated cancer biology, medicinal chemistry, and data sciences create selective small molecules.
- STX-478 validated mutant-selective PI3Kα targeting with favorable early tolerability and efficacy.
- Pipeline spans three clinical candidates plus discovery programs against previously undruggable targets.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$420M
Above
Industry Average
Funded Over
4 Rounds
Lightspeed Venture PartnersGrowth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -20%2 year growth
↑ 0%Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today